Specialty services drive growth, but margin pressure remains
- Cencora is a key middleman in the drug supply chain, especially in U.S. pharmaceutical distribution.
- Q3 FY2026 brought another guidance raise, pushing expected full-year adjusted EPS to $17.75 to $17.95.
- GLP-1 drugs continue lifting sales, but manufacturer price reductions and lower margins offset some of that growth.
- OneOncology is outperforming expectations, providing higher-margin physician services that balance core distribution pressures.
- The company plans to merge MWI Animal Health with Covetrus, advancing its strategy to shed non-core assets.
A better setup, with a price question
Cencora has improved its near-term story. In Q3 FY2026, management raised full-year adjusted EPS guidance to $17.75 to $17.95, driven by strong core execution and outperformance from OneOncology. The company is also taking action on its non-core assets, announcing a merger of MWI Animal Health with Covetrus.
The bull case relies on scale and specialty services. Cencora remains hard to replace in the U.S. drug market. It has massive reach, deep customer links, and rising GLP-1 volumes. At the same time, acquisitions like RCA and OneOncology are moving the company into higher-margin physician services that offset margin compression in the core distribution business.
The bear case centers on structural headwinds and debt. GLP-1 drugs add billions in revenue but pressure margins, and manufacturer list price reductions created a $2.4 billion headwind in Q3 alone. Customer concentration with Walgreens Boots Alliance remains a major risk under its new private equity ownership.
This is not a clean bargain story. The company is executing well, but the balance sheet carries more debt after the OneOncology deal. The stock price requires consistent earnings growth to justify itself, and the market will watch closely to see if the U.S. distribution segment can maintain its double-digit operating income growth.
Moving medicines at huge scale
Cencora makes most of its money by buying medicines and healthcare products, then distributing them to pharmacies, health systems, doctors, and other healthcare providers. The business runs on very high sales volume and thin margins, so small changes in product mix or pricing can matter a lot.
The U.S. Healthcare Solutions segment is the center of the company. It generates the vast majority of revenue, with growth currently driven by GLP-1 medications and specialty distribution. Cencora is successfully using physician service platforms like OneOncology to pull higher margins out of this segment.
International Healthcare Solutions is smaller but has shown recent improvement. The segment depends on European distribution and a recovery in global specialty logistics to maintain operating income growth.
Cencora is actively pruning the business. It moved areas such as animal health into an Other category to review strategic alternatives. The company has now agreed to merge MWI Animal Health with Covetrus, proving it is willing to exit non-core operations to focus on human health distribution.
What flows through Cencora
Brand-name pharmaceuticals
These are patented drugs sold through Cencora’s large distribution network. They drive a large amount of revenue, but manufacturer price reductions can limit profits.
Generic drugs and biosimilars
These are lower-cost versions of older medicines or biologic drugs. They help Cencora stay important to pharmacies and health systems as patents expire.
Specialty pharmaceuticals
These drugs often treat complex diseases and are used by hospitals and physician practices. Specialty distribution is one of the stronger parts of the U.S. segment.
GLP-1 diabetes and weight-loss drugs
GLP-1 products are adding major sales volume. In Q3 FY2026, U.S. GLP-1 sales rose by $2.3 billion year over year, though they carry lower gross profit margins.
Physician services platforms
RCA and OneOncology give Cencora more direct exposure to specialty physician practices. These businesses lift overall margins but add integration risk.
Animal health products
Animal health is currently held in the Other category. Cencora has agreed to merge MWI Animal Health with Covetrus to exit the space.
Where revenue comes from
Segment shares use Q2 FY2026 revenue before intersegment eliminations. U.S. Healthcare Solutions dominates the mix, and Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue.
What could break the story
WBA relationship reset
High impact · Medium oddsWalgreens Boots Alliance and Boots together accounted for about 25% of Cencora revenue in fiscal 2025. WBA was acquired by Sycamore Partners in August 2025, and the new private equity owners could seek changes to long-term agreements. That could affect volumes, pricing, or contract terms.
Lower-margin GLP-1 mix
Medium impact · High oddsGLP-1 drugs are a growth driver, but they have lower gross profit margins. Meanwhile, manufacturer list price reductions represented a $2.4 billion headwind to revenue growth in Q3. If GLP-1s outpace higher-margin areas, margin gains will fade.
MWI Animal Health merger closing
Medium impact · Medium oddsCencora has an agreement to merge MWI Animal Health with Covetrus. The deal requires regulatory approval, and management noted it would create a $150 million operating income headwind if it closes midway through the fiscal year. Delays could drag out uncertainty.
Debt-funded OneOncology deal
High impact · Medium oddsCencora acquired the majority of OneOncology in early 2026 for $4.6 billion in cash, funded heavily with new debt. While it is outperforming expectations early on, if the business misses targets later, leverage and investor trust could both suffer.
In one breath
What does Cencora actually do?
Cencora distributes medicines and healthcare products to pharmacies, hospitals, doctors, and other providers. It also offers services around specialty drugs, physician practices, and global commercialization.
Why do GLP-1 drugs matter for Cencora?
GLP-1 drugs for diabetes and weight loss are driving massive sales growth through Cencora’s network. The catch is that Cencora says these products carry lower gross profit margins, limiting profit growth.
Why did Cencora buy OneOncology?
OneOncology gives Cencora deeper ties to community oncology practices. The goal is to add higher-margin services and strengthen Cencora’s position in specialty pharmaceuticals.
What is the biggest customer risk?
WBA is the key risk because Walgreens and Boots together were about 25% of fiscal 2025 revenue. New private equity ownership adds uncertainty around store closures, contract terms, pricing, and volume.
